Overall, our results showed that combined therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12 had enhanced anti-HCC effect at the in vitro and in vivo levels, and was closely associated with enhanced activation of apoptosis and anti-tumor immunity and repression of tumor angiogenesis and vascularization. The gene discussed is TNFSF10; the disease is neoplasm.